Bass revs up Revlimid challenge

Hedge fund manager Kyle Bass filed a second inter partes review (IPR) challenging a patent covering Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG), the latest in a string of challenges.

The Coalition for Affordable Drugs VI, an entity associated with Bass, filed the IPR on Thursday with the U.S. Patent and Trademark Office challenging U.S. Patent No. 5,635,517. The petition challenges on the grounds of obviousness the patent's claims covering methods of administering thalidomide analogs to reduce tumor necrosis factor (TNF) alpha in mammals and the chemical structure of certain thalidomide analogs. ...